Cipla USA, Inc. recalls Lanreotide Injection
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Presence of Particulate Matter.
- Products
-
- Lanreotide Injection
- Company
- Cipla USA, Inc.
- Where it was sold
-
Nationwide in the USA
Nationwide
- Units affected
- 15,221 syringes
- About this recall
- Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67